M&A Deal Summary

Diplomat Pharmacy Acquires BioRx

On April 1, 2015, Diplomat Pharmacy acquired life science company BioRx from Symmetric Capital for 210M USD

Acquisition Highlights
  • This is Diplomat Pharmacy’s 1st transaction in the Life Science sector.
  • This is Diplomat Pharmacy’s 2nd largest (disclosed) transaction.
  • This is Diplomat Pharmacy’s 3rd transaction in the United States.
  • This is Diplomat Pharmacy’s 1st transaction in Ohio.

M&A Deal Summary
Date 2015-04-01
Target BioRx
Sector Life Science
Buyer(s) Diplomat Pharmacy
Sellers(s) Symmetric Capital
Deal Type Add-on Acquisition
Deal Value 210M USD

Target

BioRx

Cincinnati, Ohio, United States
BioRx LLC is a specialized pharmacy and infusion services provider that provides treatments for patients with ultra-orphan and rare, chronic diseases.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Diplomat Pharmacy

Flint, Michigan, United States
Category Company
Founded 1975
Sector Healthcare Services
Employees1,565
Revenue 5.5B USD (2018)
DESCRIPTION

Diplomat Pharmacy, Inc. is a provider of medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions.

DEAL STATS #
Overall 3 of 10
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 3 of 10
State (Ohio) 1 of 1
Country (United States) 3 of 10
Year (2015) 1 of 2
Size (of disclosed) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-06-27 MedPro Rx

Raleigh, North Carolina, United States

MedPro Rx, Inc. is a provider of specialized pharmacy services.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-19 Burmans Specialty Pharmacy

Brookhaven, Pennsylvania, United States

Burmans Specialty Pharmacy LLC is a provider of individualized patient care with a primary focus on the challenging condition of hepatitis C.

Buy $73M

Seller(S) 1

SELLER

Symmetric Capital

Burlington, Massachusetts, United States

Investor Investor Investor

Category Private Equity Firm
Founded 2007
PE ASSETS 202M USD
Size Small
Type Sector Agnostic
DESCRIPTION

Symmetric Capital is a private equity firm that invests in profitable growth companies in the US and Canada. Symmetric seeks to invest $5 to $25 million to help fund shareholder liquidity needs, growth, acquisitions, or debt reduction. Symmetric will consider majority or minority positions and typically looks for market-leading companies owned by their founders, a family, or small partnership. Sectors of interest include business services, healthcare and life sciences, software, IT services, applied technology, industrial products, education, logistics and distribution, and consumer products. Symmetric was formed in 2007 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 11 of 14
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 9 of 11
State (Ohio) 2 of 2
Country (United States) 10 of 13
Year (2015) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-29 Chantest

Cleveland, Ohio, United States

ChanTest, is a provider of specialized laboratory testing services for drug development. ChanTest specializes in measuring interactions between drug candidates and proteins known as ion channels.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-09 Biomedical Structures

Warwick, Rhode Island, United States

Biomedical Structures LLC is a developer and manufacturer of biomedical textile implants, while MPC focuses on the development and manufacturing of precise polymer components.

Sell -
Mergr

Product

Company

Legal